e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The interleukin-13 paradox in asthma: effective biology, ineffective biologicals
Parameswaran Nair, Paul M. O'Byrne
Source:
Eur Respir J, 53 (2) 1802250; 10.1183/13993003.02250-2018
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Parameswaran Nair, Paul M. O'Byrne. The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. Eur Respir J, 53 (2) 1802250; 10.1183/13993003.02250-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Evidence of early abnormal airways’ inflammation in children with type 1 diabetes
The impact of anti-IgE treatment on the airway microbiome in asthma.
SCREENING FOR UNDERDIAGNOSED CHILDHOOD ASTHMA IN BATUMI (GEORGIA)
Related content which might interest you:
Targeting airway inflammation in asthma: current and future therapies
Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment
Year: 2009
Targeting airway inflammation in asthma: current and future therapies
Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies
Year: 2009
New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5
Source: Eur Respir J 2001; 17: 499-506
Year: 2001
A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006
Biological and therapeutic implications of the united airways disease concept
Source: Annual Congress 2005 - PG18 - Inter-relationships between upper and lower airway diseases
Year: 2005
New phenotyping of corticosteroid-resistant asthma based on molecular mechanisms
Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology
Year: 2005
The basic science behind asthma biologics
Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost?
Year: 2018
New and future developments of therapy for asthma in children
Source: Eur Respir Mon 2012; 56: 224-234
Year: 2012
Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
Source: Eur Respir Rev 2015; 24: 594-601
Year: 2015
Emerging biologic approaches for the treatment of difficult to control asthma
Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma
Year: 2017
Introduction: pharmacogenetic approaches in the treatment of asthma
Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology
Year: 2005
Biologic therapies in paediatric severe asthma
Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma
Year: 2020
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
Do we need new therapies for noneosinophilic asthma?
Source: Annual Congress 2004 - Noneosinophilic asthma
Year: 2004
What is the role of oral corticosteroids in the era of biologics in asthma?
Source: International Congress 2019 – State of the art session: Airway disease
Year: 2019
Airway inflammation in asthma: current and future targets and therapies
Source: Breathe 2010; 6: 245-252
Year: 2010
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Are we really transforming asthma and COPD management with biologics?
Source: International Congress 2018 – State of the art session: Airways disease
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept